[go: up one dir, main page]

ATE402713T1 - Genetisch manipulierte herpesviren zur behandlung von tumoren - Google Patents

Genetisch manipulierte herpesviren zur behandlung von tumoren

Info

Publication number
ATE402713T1
ATE402713T1 AT06009428T AT06009428T ATE402713T1 AT E402713 T1 ATE402713 T1 AT E402713T1 AT 06009428 T AT06009428 T AT 06009428T AT 06009428 T AT06009428 T AT 06009428T AT E402713 T1 ATE402713 T1 AT E402713T1
Authority
AT
Austria
Prior art keywords
tumors
treatment
herpes viruses
genetically manipulated
genetically
Prior art date
Application number
AT06009428T
Other languages
English (en)
Inventor
Ralph Weichselbaum
Bernard Roizman
Richard Whitley
Original Assignee
Arch Dev Corp
Uab Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arch Dev Corp, Uab Research Foundation filed Critical Arch Dev Corp
Application granted granted Critical
Publication of ATE402713T1 publication Critical patent/ATE402713T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/763—Herpes virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16622—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16632—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT06009428T 1999-02-05 2000-02-04 Genetisch manipulierte herpesviren zur behandlung von tumoren ATE402713T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US24474899A 1999-02-05 1999-02-05

Publications (1)

Publication Number Publication Date
ATE402713T1 true ATE402713T1 (de) 2008-08-15

Family

ID=22923971

Family Applications (2)

Application Number Title Priority Date Filing Date
AT00908465T ATE325615T1 (de) 1999-02-05 2000-02-04 Genetische manipulierte herpesviren zur behandlung von tumoren
AT06009428T ATE402713T1 (de) 1999-02-05 2000-02-04 Genetisch manipulierte herpesviren zur behandlung von tumoren

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT00908465T ATE325615T1 (de) 1999-02-05 2000-02-04 Genetische manipulierte herpesviren zur behandlung von tumoren

Country Status (10)

Country Link
US (3) US20030207829A9 (de)
EP (2) EP1150696B1 (de)
JP (1) JP4623832B2 (de)
AT (2) ATE325615T1 (de)
AU (2) AU772471B2 (de)
CA (1) CA2361892C (de)
DE (2) DE60039730D1 (de)
DK (1) DK1695714T3 (de)
ES (2) ES2263454T3 (de)
WO (1) WO2000045853A2 (de)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7470426B1 (en) 1997-10-09 2008-12-30 Wellstat Biologics Corporation Treatment of neoplasms with viruses
US20030044384A1 (en) 1997-10-09 2003-03-06 Pro-Virus, Inc. Treatment of neoplasms with viruses
WO2000062735A2 (en) 1999-04-15 2000-10-26 Pro-Virus, Inc. Treatment of neoplasms with viruses
US7780962B2 (en) 1997-10-09 2010-08-24 Wellstat Biologics Corporation Treatment of neoplasms with RNA viruses
US8147822B1 (en) 1999-09-17 2012-04-03 Wellstat Biologics Corporation Oncolytic virus
AUPQ425699A0 (en) 1999-11-25 1999-12-23 University Of Newcastle Research Associates Limited, The A method of treating a malignancy in a subject and a pharmaceutical composition for use in same
AU2002307749A1 (en) * 2001-05-09 2002-11-25 M's Science Corporation Composition and method for treating cancer using herpes virus
WO2003073918A2 (en) * 2002-03-01 2003-09-12 Sloan-Kettering Institute For Cancer Research Prevention of recurrence and metastasis of cancer
JP2004099584A (ja) 2002-05-02 2004-04-02 Keio Gijuku Ｈｓｖを用いた抗腫瘍剤
US7501126B2 (en) 2002-10-07 2009-03-10 The University Of Chicago Targeting of herpes simplex virus to specific receptors
AU2002953436A0 (en) 2002-12-18 2003-01-09 The University Of Newcastle Research Associates Limited A method of treating a malignancy in a subject via direct picornaviral-mediated oncolysis
WO2006002394A2 (en) 2004-06-24 2006-01-05 New York University Avirulent oncolytic herpes simplex virus strains engineered to counter the innate host response
WO2008141151A2 (en) * 2007-05-09 2008-11-20 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Synthetic herpes simplex viruses type-1 for treatment of cancers
WO2009148488A2 (en) * 2008-05-29 2009-12-10 The General Hospital Corporation Use of oncolytic herpes viruses for killing cancer stem cells
WO2016201450A2 (en) * 2015-06-11 2016-12-15 University Of Miami Cancer treatment and diagnosis
RU2751236C2 (ru) * 2016-04-22 2021-07-12 Иммвира Ко., Лимитед КОНСТРУИРОВАНИЕ ОБЛИГАТНОГО ВЕКТОРА НА ОСНОВЕ ОНКОЛИТИЧЕСКИХ ВИРУСОВ ПРОСТОГО ГЕРПЕСА (oHSV) И КОНСТРУКЦИИ ДЛЯ ТЕРАПИИ РАКА
TWI666321B (zh) * 2017-10-23 2019-07-21 大陸商深圳市亦諾微醫藥科技有限公司 用於癌症治療的溶瘤性單純皰疹病毒（ｏＨＳＶ）專性載體及其建構體的建構
KR101974169B1 (ko) * 2018-08-10 2019-04-30 의료법인 성광의료재단 재조합 단순 헤르페스 바이러스 및 이의 제조방법
EP4013458A4 (de) * 2019-08-16 2023-05-10 Immvira Co., Limited Pharmazeutische zusammensetzungen mit onkolytischem herpes-simplex-virus zur systemischen verabreichung
AU2020405068A1 (en) 2019-12-18 2022-07-07 Stinginn Llc Substituted 1,2, 4-triazoles and methods of use
US11897888B1 (en) 2020-04-30 2024-02-13 Stinginn Llc Small molecular inhibitors of sting signaling compositions and methods of use
JP7235334B2 (ja) * 2020-11-26 2023-03-08 イムヴィラ・カンパニー・リミテッド 癌の治療に用いる腫瘍溶解性単純ヘルペスウイルス（ｏＨＳＶ）偏性ベクター及びその構築体の構築

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4769331A (en) * 1981-09-16 1988-09-06 University Patents, Inc. Recombinant methods and materials
US4859587A (en) * 1984-06-04 1989-08-22 Institut Merieux Recombinant herpes simplex viruses, vaccines and methods
US5288641A (en) * 1984-06-04 1994-02-22 Arch Development Corporation Herpes Simplex virus as a vector
US5068192A (en) * 1986-01-27 1991-11-26 Prutech Research And Development Partnership Attenuated pseudorabies virus which includes foreign DNA encoding an amino acid sequence
US4999296A (en) * 1986-04-29 1991-03-12 Novagene, Inc. Thymidine kinase negative insertion mutants of pseudorabies virus and methods for the production of same
CA2039921A1 (en) 1990-04-16 1991-10-17 Xandra O. Breakefield Transfer and expression of gene sequences into central nervous system cells using herpes simplex virus mutants with deletions in genes for viral replication
US5328688A (en) 1990-09-10 1994-07-12 Arch Development Corporation Recombinant herpes simplex viruses vaccines and methods
US5360893A (en) * 1992-07-20 1994-11-01 University Of Colorado Foundation, Inc. DNA sequences encoding proteins used to elicit and detect programmed cell death
US5593879A (en) * 1993-01-15 1997-01-14 Massachusetts Institute Of Technology Cell death genes of Drosophila melanogaster and vertebrate analogs
US5585096A (en) * 1994-06-23 1996-12-17 Georgetown University Replication-competent herpes simplex virus mediates destruction of neoplastic cells
ATE241994T1 (de) * 1996-01-25 2003-06-15 Univ Glasgow Hsv-mutant-1716 zur behandlung von mesotheliomen
CA2200633A1 (en) * 1997-03-21 1998-09-21 Yuman Fong Rapid production of autologous tumor vaccines

Also Published As

Publication number Publication date
ES2310382T3 (es) 2009-01-01
DE60027870T2 (de) 2006-12-28
CA2361892C (en) 2010-05-25
AU772471B2 (en) 2004-04-29
JP2002536347A (ja) 2002-10-29
DE60027870D1 (de) 2006-06-14
DE60039730D1 (de) 2008-09-11
ES2263454T3 (es) 2006-12-16
CA2361892A1 (en) 2000-08-10
EP1695714B1 (de) 2008-07-30
AU2004203458B2 (en) 2007-05-17
US8318691B2 (en) 2012-11-27
US20030207829A9 (en) 2003-11-06
JP4623832B2 (ja) 2011-02-02
AU2980000A (en) 2000-08-25
US8772261B2 (en) 2014-07-08
EP1150696A2 (de) 2001-11-07
US20130039890A1 (en) 2013-02-14
WO2000045853A3 (en) 2001-05-31
ATE325615T1 (de) 2006-06-15
EP1150696B1 (de) 2006-05-10
DK1695714T3 (da) 2008-11-10
WO2000045853A2 (en) 2000-08-10
US20110002890A1 (en) 2011-01-06
EP1695714A1 (de) 2006-08-30
AU2004203458A1 (en) 2004-08-26
US20020019362A1 (en) 2002-02-14

Similar Documents

Publication Publication Date Title
ATE402713T1 (de) Genetisch manipulierte herpesviren zur behandlung von tumoren
EA200600582A1 (ru) Способы и композиции для лечения вирусного гепатита с
ATE371372T1 (de) Behandlung von neoplasmen mit interferon- empfindlichen, klonalen viren
DE69830072D1 (de) Radioaktive zusammensetzungen zur behandlung von prostatatumoren
CY1113038T1 (el) Τριετεροκυκλικες ενωσεις, συνθεσεις, και μεθοδοι για τη θεραπεια καρκινου
DE69435155D1 (de) Zusuammensetzungen zur Behandlung von Krebs mittels Viren
CY1112425T1 (el) Αντισωματα αντι-ngf για την θεραπευτικη αγωγη διαφορων διαταραχων
CY1108765T1 (el) ΑΓΩΓΗ ME ΑΝΤΙΣΩΜΑΤΑ ANTI-ErbB2
FI971568A0 (fi) Menetelmä resistenttien kasvainten hoitamiseksi
DE69733834D1 (de) Thyroxin-analoge mit keiner signifikanten hormonellen aktivität zur behandlung von bösartigen tumoren
DE602004029651D1 (de) Verwendung von artemisinin zur behandlung von durch onkogene viren gebildeten tumoren und zur behandlung von viralen infektionen
ATE241994T1 (de) Hsv-mutant-1716 zur behandlung von mesotheliomen
ATE239509T1 (de) Konjugate zur behandlung von prostatakrebs
ATE197670T1 (de) Parenterales busulfan zur behandlung von malignen krankheiten
ATE165345T1 (de) Sulfonsaeurederivate zur behandlung von viruserkrankungen
DE69927688D1 (de) Antivirales Mittel in Kombination mit Strahlentherapie zur Verwendung in der Behandlung von Krebs
DE69109283D1 (de) Verfahren zur sensibilisierung von tumorzellen.
DE69729004D1 (de) Photodynamische therapie zur behandlung von osteosrthritis
NO20002412D0 (no) FremgangsmÕte for behandling av tumorer og tumorceller ved anvendelse av ex vivo aktiverte T celler
DK1237562T3 (da) Fremgangsmåde til fremstilling af mikania-ekstrakter, som indeholder mikanolid og dihydromikanolid, og anvendelse i behandlingen af prolifererende sygdomme
FI961380A0 (fi) Koostumuksia virusten aiheuttamien kasvainten ehkäisemiseksi ja hoitamiseksi
DK0986393T3 (da) Anvendelse af et nitroxid eller et prodrug heraf ved profylaktisk og terapeutisk behandling af cancer
DE69922364D1 (de) Verfahren zur immunisierung und behandlung von h. pylori infektion
ATE356144T1 (de) Regulatorische/entfaltende peptide von ezrin
DE69806062D1 (de) Kombinationstherapie zur behandlung von aids

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1695714

Country of ref document: EP